Meibomian gland dysfunction. Meibomian gland dysfunction of eyelid
Conditions
Interventions
Intervention 1: Intervention group 1: Ophthalmic cleansing shampoo containing TTO (EYESOL), once a day, for three months. After washing hands, a cotton bud was to be moistened with the solution. Then,
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Adult patients aged 18 to 70 years with meibomian gland dysfunction diagnosis in slit-lamp examination
Exclusion criteria
Exclusion criteria: Systemic medications affecting tear production (antihistamines, antidepressants and etc.) Contact lenses Eyelid malfunction such as lagophthalmous History of ocular surgery Other ocular diseases involving ocular surface (Stevens-Johnson, Sjogren's syndrome, chemical damage, history of head radiation) Systemic diseases involving ocular surface ( Diabetes mellitus, rosacea, neurologic diseases) Infectious keratoconjunctivitis Any topical medication such as steroids during last four weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Meibomian gland expressibility. Timepoint: At first (before treatment), one and three months after treatment. Method of measurement: It was determined by simultaneous expression from approximately eight glands (occupying central one third of the lower lid length) by firm digital pressure. It was scored according to the number of the eight glands from which a fluid secretion can be expressed, regardless of its qualitative appearance (0 = all glands expressible, 1 = 3–4 glands expressible, 2 = 1–2 glands expressible, 3 = no glands expressible).;Meibum quality. Timepoint: At first (before treatment), one and three months after treatment. Method of measurement: Quality of expressed lipid was evaluated in appearance and scored as follows; clear fluid (0), cloudy fluid (1), viscous fluid containing particulate matter (2) and densely opaque, inspissated, toothpaste-like material (3). Meibum quality score was defined by summation of scores of expressed glands.;Occurrence of possible side effects. Timepoint: At first (before treatment), one and three months after treatment. Method of measurement: Occurrence of itching, burning, redness and irritating symptoms of eyes and eyelid skin after starting treatment.;Ocular surface symptoms score in DEQ5 questionnair. Timepoint: At first (before treatment), one and three months after treatment. Method of measurement: DEQ5 questionnair.;Conjunctival redness. Timepoint: At first (before treatment), one and three months after treatment. Method of measurement: Conjunctival vessel dilation and hyperemia.;Fluorescein staining of the cornea and conjunctiva. Timepoint: At first (before treatment), one and three months after treatment. Method of measurement: Oxford scoring system after fluorescein staining.;Tear break up time in second. Timepoint: At first (before treatment), one and three months after treatment. Method of measurement: After applying fluorescein dye, the patient blinks several times and then we ask her/him not to blink anymor | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhodsieh Zamani
Mashhad University of Medical Sciences
Outcome results
None listed